Event-free survival following early endometrial events in breast cancer patients treated with anti-hormonal therapy: A nationwide claims data study

Tamoxifen, an anti-estrogen agent that can suppress breast cancer, has been reported to increase endometrium-related adverse events. There are no guidelines for screening tamoxifen-treated patients for endometrial disease. We analyzed nationwide claims data related to endometrial diseases to investi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yura, Park, Yu Rang, Kim, Hae Reong, Lee, Jong Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336644/
https://www.ncbi.nlm.nih.gov/pubmed/30633178
http://dx.doi.org/10.1097/MD.0000000000013976

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336644/
https://www.ncbi.nlm.nih.gov/pubmed/30633178
http://dx.doi.org/10.1097/MD.0000000000013976

Ejemplares similares